Expertise in
20
conditions

Nadege Corradini

Lyon, FR 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
20
conditions
Lyon, FR 
OverviewLocationsClinical Research

Overview

Nadege Corradini practices in Lyon, France. Ms. Corradini is highly rated in 20 conditions, according to our data. Her top areas of expertise are Adult Soft Tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, Rhabdomyosarcoma, and Bone Marrow Aspiration.

Her clinical research consists of co-authoring 141 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Female

Locations

Lyon, France
Other Locations
Nantes, 44093, France
Contre, 44035, France
Nancy, 54000, France
Rouen, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Etoposide, Vincristine, Carboplatin, Cyclophosphamide, Thiotepa
Study Phase: Phase 2
Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Phase I Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: September 22, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: July 23, 2025
Intervention Type: Drug
Study Drugs: LY3295668 Erbumine, Topotecan, Cyclophosphamide
Study Phase: Phase 1
A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours
A Phase 1, Multicentre, Open-Label, Dose-Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Patients With Recurrent or Refractory Solid Tumours
Enrollment Status: Terminated
Publish Date: July 16, 2025
Intervention Type: Drug
Study Phase: Phase 1
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.
RNASARC - Molecular Screening Program of Soft Tissue Sarcomas With Complex Genomic Profile to Detect NTRK1/2/3, ROS1 or ALK Gene Fusions.
Enrollment Status: Active_not_recruiting
Publish Date: August 26, 2024
Intervention Type: Genetic
Study Phase: Not Applicable
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.
A Multicentre, Open-label, Phase I-II Study Evaluating the Combination of a MEK Inhibitor and a PDL1 Inhibitor in Pediatric and Adult Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma.
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Cobimetinib, Atezolizumab
Study Phase: Phase 1/Phase 2
Conservative Treatments of Retinoblastoma
Conservative Treatments of Retinoblastoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug, Device, Radiation
Study Drugs: VP16, Carboplatin, Melphalan, VP16, Carboplatin, Vincristin, Carboplatin + Laser Day 1 (Chemothermotherapy), Intravitreal Melphalan
Study Phase: Phase 2
View 6 Less Clinical Trials

141 Total Publications

Desmoid-Type Fibromatosis Tumors in Children After First-Line Failure: Clinical Aspects and Approaches for Subsequent Therapeutic Lines.
Desmoid-Type Fibromatosis Tumors in Children After First-Line Failure: Clinical Aspects and Approaches for Subsequent Therapeutic Lines.
Journal: Pediatric blood & cancer
Published: July 03, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Corradini's expertise for a condition
ConditionClose
View All 13 Advanced Conditions
View All 29 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile